Alpha-Gal A and Migalastat Co-Formulation for Fabry Disease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current enzyme replacement therapies for Fabry disease, such as agalsidase alfa and agalsidase beta, have limitations including slow cardiac muscle response, limited GL-3 elimination from kidney cell types, and potential immune reactions, necessitating the development of alternative therapeutic approaches to enhance enzyme delivery and stability.
Innovation Solution
A co-formulation of recombinant human α-galactosidase A enzyme with 1-deoxygalactonojirimycin, an active site-specific chaperone, is administered intravenously to stabilize the enzyme, enhance its trafficking to lysosomes, and improve tissue uptake, thereby increasing its therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If enzyme replacement therapy is administered, then α-Gal A activity is compensated, but plasma half-life is short and tissue uptake is limited
Solution Approach 1:
The patent introduces a chaperone molecule as an intermediary that binds to the α-Gal A enzyme and facilitates its stabilization and trafficking. This chaperone acts as a mediator between the administered enzyme and the cellular uptake mechanisms, extending plasma half-life while improving tissue delivery efficiency
Solution Approach 2:
The invention creates a composite therapeutic formulation combining the α-Gal A enzyme with chaperone molecules. This composite approach allows the enzyme-chaperone complex to exhibit extended circulation half-life and enhanced cellular uptake properties that neither component possesses alone
2Reliability
If ERT is administered, then enzyme activity is restored, but immune reactions occur
Solution Approach 1:
The chaperone molecule serves as a protective intermediary that shields the administered enzyme from immune system recognition. By forming a stable complex, the chaperone reduces the immunogenicity of the recombinant enzyme while maintaining its catalytic activity
Solution Approach 2:
The invention modifies the physical-chemical parameters of the enzyme formulation by combining it with chaperone molecules. This parameter change in the form of a protein complex reduces immune recognition while preserving enzymatic function
3Reliability
If ERT is administered, then substrate accumulation is reduced, but cardiac muscle response is slow and kidney GL-3 elimination is limited
Solution Approach 1:
The chaperone molecule acts as a delivery intermediary that enhances the trafficking of the enzyme to specific tissues including cardiac muscle and kidney. This mediator facilitates faster and more efficient cellular uptake, accelerating the response in previously refractory tissues
Solution Approach 2:
The enzyme-chaperone complex exhibits enhanced local delivery properties to specific target tissues. The chaperone facilitates preferential uptake in cardiac and renal tissues, providing localized therapeutic enhancement where it is most needed
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The co-formulation significantly increases the plasma half-life and tissue uptake of α-galactosidase A, leading to enhanced GL-3 reduction in tissues and improved therapeutic outcomes for Fabry disease, with potential for reduced immune reactions and improved stability of the enzyme.
Implementation Method 1
1-deoxygalactonojirimycin and its salt, 1-deoxygalactonojirimycin hydrochloride (also known by its United States Adopted_name (USAN), migalastat hydrochloride) acts as a pharmacological chaperone for mutant α-Gal A by selectively binding to the enzyme, thereby increasing its stability
Implementation Method 2
This stabilization of α-Gal A allows the cell's quality control mechanisms to recognize the enzyme as properly folded so that trafficking of the enzyme to the lysosome is increased
Implementation Method 3
The co-formulation significantly increases the plasma half-life and tissue uptake of α-galactosidase A
Implementation Method 4
The enzyme deficiency leads to intracellular accumulation of the substrate, globotriaosylceramide (GL-3) in the vascular endothelium and visceral tissues throughout the body
Data Source
AI summary
The present application provides compositions comprising α-galactosidase A in combination with an active site-specific chaperone for the α-galactosidase A, and methods for treating Fabry disease in a subject in need thereof, that includes a method of administering to the subject such compositions. The present application also provides methods for increasing the in vitro and in vivo stability of an α-galactosidase A enzyme formulation. The present application also provides methods for treating Fabry disease using intravenous administration of 1-deoxygalactonojirimycin.